OncoMatch/Clinical Trials/NCT05808634
Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma.
Is NCT05808634 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies BA3182 for advanced adenocarcinoma.
Treatment: BA3182 — The objective of this study is to assess safety and efficacy of BA3182 in Advanced Adenocarcinoma
Check if I qualifyExtracted eligibility criteria
Performance status
ECOG 0–1(Restricted strenuous activity)
Lab requirements
Blood counts
Adequate hematological function
Kidney function
Adequate renal function
Liver function
Adequate liver function
Adequate renal function; Adequate liver function; Adequate hematological function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UC Irvine · Irvine, California
- USC Norris Comprehensive Cancer Center · Los Angeles, California
- Yale Cancer Center · New Haven, Connecticut
- Northwestern University · Chicago, Illinois
- University of Illinois · Chicago, Illinois
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify